Clinical Lung Cancer [SEP] publisher
Clinical Lung Cancer
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
History.
"Clinical Lung Cancer" is indexed in "Index Medicus/Pubmed, EMBASE (Excerpta Medica), Current Contents/Clinical Medicine, Science Citation Index Expanded, CINAHL", and "Chemical Abstracts." It is published six times annually.
Scope.
"Clinical Lung Cancer" publishes articles on detection, diagnosis
that have been approved or are progressing to late-stage clinical development.
TCIs in clinical development KRAS and lung, colorectal cancer.
AMG 510 by Amgen is a KRAS p.G12C covalent inhibitor that has recently finished Phase I clinical trial. The drug elicited partial responses in half of evaluable patients with KRAS G12C-mutant non–small cell lung cancer, and led to stable disease in most evaluable patients with colorectal (or appendix) cancer.
TCIs in clinical development EGFR and lung cancer.
The second generation EGFR